CiplaCPLFY 94 PB Ratio is 0.00 as of Jun. 26, 2026. GuruFocus rates CPLFY with a GF Score™ of 94/100. The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Cipla ranks worse than 72.56% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Cipla's share price is $0.00. Cipla's Book Value per Share for the quarter that ended in Mar. 2026 was $4.59. Hence, Cipla's PB Ratio of today is 0.00.
The historical rank and industry rank for Cipla's PB Ratio or its related term are showing as below:
CPLFY'
s PB Ratio Range Over the Past 10 Years
Min: 2.16 Med: 3.69 Max: 4.73
Current: 3.18
During the past 13 years, Cipla's highest PB Ratio was 4.73. The lowest was 2.16. And the median was 3.69.
CPLFY's PB Ratio is ranked worse than 72.56% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs CPLFY: 3.18
During the past 12 months, Cipla's average Book Value Per Share Growth Rate was 10.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cipla was 35.20% per year. The lowest was 7.60% per year. And the median was 13.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cipla PB Ratio Related Terms
Cipla PB Ratio Historical Data
* Premium members only.
The historical data trend for Cipla's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cipla's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cipla's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cipla (CPLFY) has a PB Ratio of 0.00 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cipla and its competitors. Over the past decade, Cipla's PB Ratio has ranged from 2.16 to 4.73. According to the industry distribution chart, Cipla ranks #669 out of 922 companies in the Drug Manufacturers industry, placing it in the top 72.6%.
Is Cipla's PB Ratio too high?
Cipla's current PB Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 2.16 to a high of 4.73. Based on the distribution chart, Cipla ranks #669 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #669 out of 922 companies for PB Ratio. This places Cipla in the lower half of its industry. The industry median PB Ratio is 1.83. Historically, Cipla's own PB Ratio has ranged from 2.16 to 4.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current PB Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current PB Ratio of 0.00. The current PB Ratio is 0.00. Cipla's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cipla (CPLFY), the current PB Ratio is 0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 